Janux Therapeutics, Inc. (JANX) Tops Q3 EPS by 23c
Tweet
Share
E-mailGet Alerts JANX Hot Sheet
Join SI Premium – FREE
Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.39), $0.23 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10 million versus the consensus estimate of $2.88 million.
For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Kalyan Jewellers India Ltd (KALYANKJ:IN) at Buy
- JPMorgan cut off lending activity for Situational Awareness - FT
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
